Revance Therapeutics Inc (RVNC)
2.82
-0.15
(-5.05%)
USD |
NASDAQ |
Jun 14, 16:00
2.81
-0.01
(-0.35%)
After-Hours: 20:00
Revance Therapeutics Research and Development Expense (Annual): 79.41M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 79.41M |
| December 31, 2022 | 101.29M |
| December 31, 2021 | 116.26M |
| December 31, 2020 | 125.80M |
| December 31, 2019 | 102.86M |
| December 31, 2018 | 92.50M |
| December 31, 2017 | 80.36M |
| Date | Value |
|---|---|
| December 31, 2016 | 50.38M |
| December 31, 2015 | 47.53M |
| December 31, 2014 | 33.39M |
| December 31, 2013 | 27.83M |
| December 31, 2012 | 32.71M |
| December 31, 2011 | 22.74M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
79.41M
Minimum
2023
125.80M
Maximum
2020
105.12M
Average
102.86M
Median
2019
Research and Development Expense (Annual) Benchmarks
| AbbVie Inc | 7.675B |
| Design Therapeutics Inc | 57.06M |
| Humacyte Inc | 76.55M |
| Context Therapeutics Inc | 17.78M |
| AN2 Therapeutics Inc | 54.87M |